Regional, but not systemic recruitment/expansion of dendritic cells by a pluronic-formulated Flt3-ligand plasmid with vaccine adjuvant activity

Vaccine

Volumn 21, Issue 21-22, 2003, Pages 3019-3029

  Sang, Hongxun ^a,b   Pisarev, Vladimir M ^b   Munger, Corey ^b   Robinson, Simon ^b   Chavez, Jennifer ^b   Hatcher, Lori ^b   Parajuli, Prahlad ^c   Guo, Yajun ^d   Talmadge, James E ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Dendritic cells; Flt3 ligand; Gag; Plasmid vaccine; Pluronic formulation

Indexed keywords

CD11 ANTIGEN; DNA VACCINE; DRUG CARRIER; FLT3 LIGAND; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; MESSENGER RNA; PLASMID VECTOR; PVAX GAG VACCINE; SP 1017; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BIOACCUMULATION; CELL ACTIVITY; CELL COUNT; CELL INFILTRATION; CELL TYPE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG ACTIVITY; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOASSAY; IMMUNOTOXICITY; LYMPH NODE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; T LYMPHOCYTE;

EID: 0037705432     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00143-9     Document Type: Article

References (47)

1. Nestle F.O., Banchereau J., Hart D. Dendritic cells: on the move from bench to bedside. Nat. Med. 7(7):2001;761-765.
2. Nouri-Shirazi M., Banchereau J., Fay J., Palucka K. Dendritic cell based tumor vaccines. Immunol. Lett. 74(1):2000;5-10.
3. Liu Y.J., Kanzler H., Soumelis V., Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat. Immunol. 2(7):2001;585-589.
4. Pulendran B., Banchereau J., Maraskovsky E., Maliszewski C. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol. 22(1):2001;41-47.
5. Lutzker S.G., Lattime E.C. Use of dendritic cells to immunize against cancers overexpressing p53. Clin. Cancer Res. 7(1):2001;2-4.
6. Lyman S.D., James L., Vanden Bos T.et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell. 75(6):1993;1157-1167.
7. Hannum C., Culpepper J., Campbell D.et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature. 368(6472):1994;643-648.
8. Lyman S.D., James L., Johnson L.et al. Cloning of the human homologue of the murine Flt3-ligand: a growth factor for early hematopoietic progenitor cells. Blood. 83(10):1994;2795-2801.
9. McKenna H.J. Role of hematopoietic growth factors/Flt3-ligand in expansion and regulation of dendritic cells. Curr. Opin. Hematol. 8(3):2001;149-154.
10. Antonysamy M.A., Thomson A.W. Flt3-ligand (FL) and its influence on immune reactivity. Cytokine. 12(2):2000;87-100.
11. Brasel K., McKenna H.J., Morrissey P.J. Hematologic effects of Flt3-ligand in vivo in mice. Blood. 88(6):1996;2004-2012.
12. Xu Z.X., Zhu J.K., Zhang Z.H.et al. Recombinant human Flt3-ligand exerts both direct and indirect effects on hematopoiesis. Indian J. Pharmacol. 32:2001;1-6.
13. Pulendran B., Banchereau J., Burkeholder S.et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. 165(1):2000;566-572.
14. Mosley R.L., Parajuli P., Pisarev V.et al. Flt3-ligand augmentation of T cell mitogenesis and expansion of type 1 effector/memory T cells. Int. Immunopharmacol. 2(7):2002;925-940.
15. Pisarev V.M., Parajuli P., Mosley R.L.et al. Flt3-ligand enhances the immunogenicity of a gag-based HIV-1 vaccine. Int. J. Immunopharmacol. 22(11):2000;865-876.
16. Kwon T.K., Park J.W. Intramuscular co-injection of naked DNA encoding HBV core antigen and Flt3-ligand suppresses anti-HBc antibody response. Immunol. Lett. 81(3):2002;229-234.
17. Pisarev V.M., Parajuli P., Mosley R.L.et al. Flt3-ligand and conjugation to IL-1B peptide as adjuvants for a type 1. T cell response to an HIV gag p17 vaccine. Vaccine. 17-18:2002;2358-2368.
18. O'Keeffe M., Hochrein H., Vremec D.et al. Effects of administration of progenipoietin 1, Flt-3 ligand, granulocyte colony-stimulating factor, and pegylated granulocyte macrophage-colony stimulating factor on dendritic cell subsets in mice. Blood. 99(6):2002;2122-2130.
19. Disis M.L., Rinn K., Knutson K.L.et al. Flt3-ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood. 99(8):2002;2845-2850.
20. Moore A.C., Kong W.P., Chakrabarti B.K., Nabel G.J. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J. Virol. 76(1):2002;243-250.
21. Parajuli P., Pisarev V., Sublet J.et al. Immunization with wild-type p53 gene sequences coadministered with Flt3-ligand induces an antigen-specific type 1 T-cell response. Cancer Res. 61:2001;8227-8234.
22. Gregory S.H., Sagnimeni A.J., Zurowski N.B., Thomson A.W. Flt3-ligand pretreatment promotes protective immunity to Listeria monocytogenes. Cytokine. 13(4):2001;202-208.
23. Lynch D.H., Andreasen A., Maraskovsky E., Whitmore J., Miller R.E., Schuh J.C.L. Flt3-ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 3(6):1997;625-631.
24. He Y., Pimenov A.A., Nayak J.V., Plowey J., Falo L.D. Jr., Huang L. Intravenous injection of naked DNA encoding secreted Flt3-ligand dramatically increases the number of dendritic cells and natural killer cells in vivo. Hum. Gene Ther. 11(4):2000;547-554.
25. Hung C.F., Hsu K.F., Cheng W.F.et al. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res. 61(3):2001;1080-1088.
26. Bonadio J. Tissue engineering via local gene delivery: update and future prospects for enhancing the technology. Adv. Drug Deliv. Rev. 44(2-3):2000;185-194.
27. Shedlock D.J., Weiner D.B. DNA vaccination: antigen presentation and the induction of immunity. J. Leukoc. Biol. 68(6):2000;793-806.
28. Schatzlein A.G. Non-viral vectors in cancer gene therapy: principles and progress. Anticancer Drugs. 12(4):2001;275-304.
29. Liu F., Song Y., Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6(7):1999;1258-1266.
30. Yew N.S., Wang K.X., Przybylska M.et al. Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid: pDNA complexes. Hum. Gene Ther. 10(2):1999;223-234.
31. Lemieux P., Guerin N., Paradis G.et al. A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle. Gene Ther. 7(11):2000;986-991.
32. Krzesicki R.F., Winterrowd G.E., Brashler J.R.et al. Identification of cytokine and adhesion molecule mRNA in murine lung tissue and isolated T cells and eosinophils by semi-quantitative reverse transcriptase-polymerase chain reaction. Am. J. Respir. Cell Mol. Biol. 16(6):1997;693-701.
33. Fushimi T., Inoue A., Koh C.S., Yamazaki M., Ishihara Y., Kim B.S. The effect of pentoxyfilline (PTX) on Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. Cell Immunol. 186(2):1998;140-146.
34. Braun S.E., Chen K., Blazar B.R.et al. Flt3-ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte macrophage-colony stimulating factor and a potential mechanism of action. Hum. Gene Ther. 10(13):1999;2141-2151.
35. Brasel K., De Smedt T., Smith J.L., Maliszewski C.R. Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood. 96(9):2000;3029-3039.
36. Fong L., Hou Y., Rivas A.et al. Altered peptide ligand vaccination with Flt3-ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 98(15):2001;8809-8814.
37. Morse M.A., Nair S., Fernandez-Casal M.et al. Preoperative mobilization of circulating dendritic cells by Flt3-ligand administration to patients with metastatic colon cancer. J. Clin. Oncol. 18(23):2000;3883-3893.
38. Wolff J.A., Malone R.W., Williams P.et al. Direct gene transfer into mouse muscle in vivo. Science. 247(4949 Pt 1):1990;1465-1468.
39. Dupuis M., Denis-Mize K., Woo C.et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J. Immunol. 165(5):2000;2850-2858.
40. Horton H.M., Anderson D., Hernandez P., Barnhart K.M., Norman J.A., Parker S.E. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc. Natl. Acad. Sci. U.S.A. 96(4):1999;1553-1558.
41. Haddad D., Ramprakash J., Sedegah M.et al. Plasmid vaccine expressing granulocyte macrophage-colony stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J. Immunol. 165(7):2000;3772-3781.
42. Hartikka J., Sukhu L., Buchner C.et al. Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxamer 188. Mol. Ther. 4(5):2001;407-415.
43. Moore A.C., Kong W.P., Chakrabarti B.K., Nabel G.J. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J. Virol. 76(1):2002;243-250.
44. Esche C., Subbotin V.M., Maliszewski C., Lotze M.T., Shurin M.R. Flt3-ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res. 58(3):1998;380-383.
45. Chen K., Braun S., Lyman S.et al. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res. 57(16):1997;3511-3516.
46. Lowrie D.B., Tascon R.E., Bonato V.L.et al. Therapy of tuberculosis in mice by DNA vaccination. Nature. 400(6741):1999;269-271.
47. Pulendran B., Smith J.L., Caspary G.et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl. Acad. Sci. U.S.A. 96(3):1999;1036-1041.